Source ForPressRelease.com

Uniza Group, an Ahmedabad based young Pharma company celebrating its first year of operations has entered into an exclusive tie-up with Lysulin Inc - innovator company from USA to launch Lysulin - a breakthrough evidence based nutritional product for Indian Market. Lysulin is patented in the USA for the prevention of protein glycation using Lysine supplements and as a method of diabetes support using a supplement.



UNIZA is a pharmaceutical venture of Pashupati Group. Company has set up a Modern, state of the art facility complying with WHO-GMP and PIC/S guidelines at Kadi near Ahmedabad, Gujarat. Having launched India business in August 2020, the company has gradually expanded its product range to over 80 SKU’s with a sale of Rs. 25 crore in the first year.



Speaking on the development, Mr. Sreekanth Seshadri, CEO and Managing Partner, Uniza Healthcare, said, "Our endeavour is to bring the best of global healthcare products to India and the launch of Lysulin, Schones and Keratizaare testimony to our commitment. Company is looking to introduce more innovative products for the first time in India. Focused on dermatology, cardiology and diabetes management we offer products that includes Anti fungals, Anti dandruff preparations, Moisturizers, Antibiotics, Anti allergic preparations, Anti acne, Multi-vitamins, Anti Hypertensives, Oral Hypoglycemic agents, Lipid Lowering agents, and Iron preparations."



"Uniza is committed to deliver high quality and cost effective formulations. Our R&D and production team ensures strict adherence to GMP guidelines and WHO quality norms for producing world class products. Our International business would mainly focus on ROW markets like Africa, LATAM, South East Asia and CIS countries and planning to file over 180 dossiers. Our Indian business is aiming to achieve sales of Rs. 100 crore in FY 2021-22," said, Mr. Saurin Parikh, MD, Uniza Group & Founder, Pashupati Group.